Odactra™ House Dust Mite – New drug approval
March 1, 2017 – The FDA announced the approval of ALK’s Odactra House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) allergen extract, as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus HDMs, or skin testing to licensed HDM allergen extracts.